Search results for " tumor"

showing 10 items of 3819 documents

Circulating Tumor Cells (CTCs): A Unique Model of Cancer Metastases and Non-invasive Biomarkers of Therapeutic Response

2021

Late-stage cancer metastasis remains incurable in the clinic and is the major cause death in patients. Circulating tumor cells (CTCs) are thought to be metastatic precursors shed from the primary tumor or metastatic deposits and circulate in the blood. The molecular network regulating CTC survival, extravasation, and colonization in distant metastatic sites is poorly defined, largely due to challenges in isolating rare CTCs. Recent advances in CTC isolation and ex vivo culture techniques facilitates single-cell omics and the development of related animal models to study CTC-mediated metastatic progression. With these powerful tools, CTCs can potentially be used as non-invasive biomarkers pr…

liquid biopsybusiness.industryMini Reviewnon-invasive biomarkertherapeutic responseCancercirculating tumor cellsQH426-470Omicsmedicine.diseasemicrofluidic engineeringPrimary tumorExtravasationCirculating tumor cellcancer metastasisGeneticsCancer researchMolecular MedicineMedicineLiquid biopsyStage (cooking)businessGenetics (clinical)Ex vivoFrontiers in Genetics
researchProduct

A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.

2015

Background: Na+/H+ exchanger-1 (NHE-1) is involved in pH regulation and is up-regulated in different malignancies. Activation of NHE-1 is one way for allowing cells to avoid intracellular acidification and protect them against apoptosis. Inhibitors of NHE-1 are able to decrease intracellular pH and induce apoptosis. Some statins can also act by partial inhibition of NHE-1. This review presents progress in understanding the mechanisms of action of these inhibitors, connections with certain genetic mutations and acquired treatment resistance, as well as new patents on them. Methods: A MEDLINE search for original and review articles using key terms, Na+/H+ exchanger, leukemia, cariporide, and …

lovastatinlcsh:MedicineApoptosisPharmacologyGuanidinesAmiloridep-glycoproteinhemic and lymphatic diseasesDrug InteractionsSulfonesCation Transport ProteinsSodium-Hydrogen Exchanger 1leukemiaMyeloid leukemiaHydrogen-Ion ConcentrationSorafenibUp-RegulationLeukemiaLeukemia Myeloid AcuteImatinib MesylateSignal transductionTyrosine kinasemedicine.drugSignal TransductionSorafenibNiacinamideisoprenylationSodium-Hydrogen Exchangersbcr/ablAntineoplastic AgentsGenes ablGeneral Biochemistry Genetics and Molecular BiologystatinsPatents as TopicCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProtein Kinase Inhibitorscariporidena+/h+ exchangerTumor hypoxiabusiness.industryPhenylurea Compoundslcsh:ROsmolar Concentrationintracellular phmedicine.diseaseImatinib mesylatefms-Like Tyrosine Kinase 3Fms-Like Tyrosine Kinase 3MutationCancer researchTumor Hypoxiaflt3/itdHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessHeme Oxygenase-1DNA DamageBiomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
researchProduct

IGF2BP3 Associates with Proliferative Phenotype and Prognostic Features in B-Cell Acute Lymphoblastic Leukemia

2021

Simple Summary Although the prognosis of acute lymphoblastic leukemia (ALL) has improved significantly during the past decades, ALL remains a major cause of pediatric cancer mortality, and more accurate risk-stratification is required. We investigated IGF2BP3, which has previously been associated with aggressive cancers, and found high and subtype-specific expression of IGF2BP3 in B-cell ALL, that was associated with good outcome in high-risk patients. Results suggest that IGF2BP3 could be useful to improve stratification and prognosis of B-ALL. Abstract The oncofetal protein insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) belongs to a family of RNA-binding proteins involved i…

lähetti-RNAmRNAproliferation3122 Cancersleukemiabiomarkkeritennusteetlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensinsulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)lcsh:RC254-282Articleinsulin-like growth factor 2 mRNA-binding protein 3 (<i>IGF2BP3</i>)akuutti lymfaattinen leukemiapediatric B-cell acute lymphoblastic leukemia1182 Biochemistry cell and molecular biologysyöpätauditproteiinitprognosisproteinCancers
researchProduct

Mutant HRAS as novel target for MEK and mTOR inhibitors.

2015

HRAS is a frequently mutated oncogene in cancer. However, mutant HRAS as drug target has not been investigated so far. Here, we show that mutant HRAS hyperactivates the RAS and the mTOR pathway in various cancer cell lines including lung, bladder and esophageal cancer. HRAS mutation sensitized toward growth inhibition by the MEK inhibitors AZD6244, MEK162 and PD0325901. Further, we found that MEK inhibitors induce apoptosis in mutant HRAS cell lines but not in cell lines lacking RAS mutations. In addition, knockdown of HRAS by siRNA blocked cell growth in mutant HRAS cell lines. Inhibition of the PI3K pathway alone or in combination with MEK inhibitors did not alter signaling nor had an imp…

mTOR inhibitorMutantBlotting Western610 Medicine & healthApoptosisMice SCIDCell LineProto-Oncogene Proteins p21(ras)chemistry.chemical_compoundCell Line TumorNeoplasmsMedicineAnimalsHumansHRASHRAS mutationsProtein Kinase InhibitorsPI3K/AKT/mTOR pathwayCell ProliferationGeneticsMitogen-Activated Protein Kinase KinasesMEK inhibitorOncogeneCell growthbusiness.industryMEK inhibitorTOR Serine-Threonine KinasesDiphenylamineXenograft Model Antitumor AssaysTumor Burdenlung cancer10219 Clinic for Gastroenterology and HepatologyCell Transformation NeoplasticOncologychemistry10032 Clinic for Oncology and HematologyBenzamidesMutationCancer researchbladder cancer2730 OncologyBenzimidazolesRNA InterferenceSignal transductionGrowth inhibitionbusinessSignal TransductionResearch PaperOncotarget
researchProduct

Perlman syndrome: Clinical report and nine-year follow-up

2005

We present the clinical and follow-up data of a female infant with Perlman syndrome from birth to the age of 9 years. Main features of Perlman syndrome include polyhydramnios, fetal overgrowth, neonatal macrosomia, macrocephaly, dysmorphic facial features, visceromegaly, nephroblastomatosis, and a predisposition for Wilm's tumor. In our patient, the nephromegaly with nephroblastomatosis was not present at birth or during the neonatal period; it became evident in the first months of postnatal life. A Wilm's tumor was diagnosed when she was about 1 year old. Long term follow-up documents the natural history of Perlman syndrome and allows us to establish the long-term prognosis of the affected…

macrosomiaPediatricsmedicine.medical_specialtyPolyhydramniosNephroblastomatosiFetal overgrowthInternal medicineGeneticsmedicineHumansAbnormalities MultiplePerlman syndromeChildPerlman syndromeNephroblastomatosisGenetics (clinical)business.industryInfant NewbornMacrocephalyInfantWilms' tumorsyndromemedicine.diseaseEndocrinologyChild PreschoolOvergrowth syndromeNephromegalyFemaleWilm's tumormedicine.symptombusinessVisceromegalyAmerican Journal of Medical Genetics Part A
researchProduct

Effect of Magnesium Supplementation on Inflammatory Parameters: A Meta-Analysis of Randomized Controlled Trials

2022

Magnesium (Mg) may have several beneficial effects on human health outcomes. One hypothesized mechanism eliciting such effects is the action of Mg on serum inflammatory parameters. However, studies on this topic to date have several important limitations. Therefore, the present systematic review and meta-analysis aimed to summarize the current state of the art of all randomized control trials (RCTs) investigating the effects of Mg supplementation versus placebo on serum parameters of inflammation. We searched several databases until 23rd November 2021 for RCTs. Eligible studies were RCTs investigating the effect of oral Mg supplementation vs. placebo and having serum inflammatory markers as…

magnesium; inflammation; C reactive protein; tumor necrosis factor; randomized controlled trial; meta-analysisNutrition and DieteticsC reactive proteinNutrition. Foods and food supplytumor necrosis factorMiddle Agedmagnesiummeta-analysisinflammationDietary Supplementsrandomized controlled trialHumansTX341-641BiomarkersRandomized Controlled Trials as TopicFood Science
researchProduct

Malignant focal lesions

2011

no abstract

malignant liver tumors CT MRSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

Utilidad clínica de la expresión de marcadores inmunohistoquímicos en el tumor vesical urotelial papilar sin invasión de la muscular propia (pTa/pT1)…

2015

Introducción: El tumor vesical urotelial papilar sin invasión de la muscular propia (TVU NoMinv) es uno de los tumores urológicos más frecuentes. A pesar del tratamiento, presenta una elevada tasa de recidiva y progresión. El hallazgo de factores pronósticos que nos indiquen su comportamiento clínico es fundamental para estratificar riesgos y ayudar al diseño de una estrategia terapéutica. Las variables anatomoclínicas clásicamente utilizadas no son del todo precisas en la evaluación pronóstica. La nueva clasificación histológica de la OMS 2004 tampoco ha conseguido este objetivo, presentando una importante variabilidad interobservador. Por ello, está en auge el estudio de marcadores molecu…

marcadores tumorales:CIENCIAS DE LA VIDA::Biología humana ::Histología humana [UNESCO]inmunohistoquimicaUNESCO::CIENCIAS MÉDICAS ::Cirugía ::Urología:CIENCIAS MÉDICAS ::Cirugía ::Urología [UNESCO]tumor vesicalUNESCO::CIENCIAS DE LA VIDA::Biología humana ::Histología humana
researchProduct

Aplicaciones de la citología exfoliativa en el diagnóstico del cáncer oral

2004

La citología exfoliativa es una técnica sencilla, no agresiva y bien aceptada por los pacientes, por lo que podría ser útil en el diagnóstico precoz del cáncer oral. Sin embargo, su utilización como método diagnóstico de atipias epiteliales y especialmente del carcinoma oral de células escamosas ha perdido importancia, sobre todo debido a su baja sensibilidad representada por el elevado número de resultados falsos negativos. Se atribuye esta baja sensibilidad a diversos factores, entre ellos: toma inadecuada de la muestra, error en la técnica e interpretación subjetiva de los hallazgos citológicos. Afortunadamente, en los últimos tiempos, el desarrollo del análisis cuantitativo, la citomorf…

marcadores tumoralesUNESCO::CIENCIAS MÉDICAScitomorfologíaanálisis del ADNOdontologíaCáncer oralcitología exfoliativa:CIENCIAS MÉDICAS [UNESCO]análisis molecularCiencias de la salud
researchProduct

Bright spots in the darkness of cancer: A review of starfishes-derived compounds and their anti-tumor action

2019

The fight against cancer represents a great challenge for researchers and, for this reason, the search for new promising drugs to improve cancer treatments has become inevitable. Oceans, due to their wide diversity of marine species and environmental conditions have proven to be precious sources of potential natural drugs with active properties. As an example, in this context several studies performed on sponges, tunicates, mollusks, and soft corals have brought evidence of the interesting biological activities of the molecules derived from these species. Also, echinoderms constitute an important phylum, whose members produce a huge number of compounds with diverse biological activities. In…

marine invertebratesOceans and SeasStarfishSea-starPharmaceutical ScienceContext (language use)Antineoplastic AgentsReviewNatural compoundMarine species03 medical and health sciencesStarfish0302 clinical medicineAnti-cancer activitymolecular drugsNeoplasmsDrug Discoverymedicinenatural compoundsAnimalsHumansGlycosidesPharmacology Toxicology and Pharmaceutics (miscellaneous)lcsh:QH301-705.5Molecular drug030304 developmental biologyAntitumor activity0303 health sciencesBiological ProductsbiologyPhylumMarine invertebrateCancerMarine invertebratesmedicine.diseasebiology.organism_classificationInvertebratesHuman tumorlcsh:Biology (General)Evolutionary biology030220 oncology & carcinogenesis
researchProduct